FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913132598> ?p ?o ?g. }

• W2913132598 endingPage "4441" @default.
• W2913132598 startingPage "4441" @default.
• W2913132598 abstract "Abstract Introduction Hyperhaploid multiple myeloma is a rare numerical aberration group defined by a range of 24-34 chromosomes. We have previously shown that hyperhaploid myeloma is associated with a poor prognosis with a 5-year survival rate of 23.1%, compared to 64% for hyperdiploid myeloma, and 80.4% for those with a normal karyotype. It is known that hyperhaploid myeloma frequently has monosomy of chromosome 17, making it a high risk group, but no data are currently available on the mutational status of this interesting sub-group, or how the copy number difference arises. Methods We analyzed data from whole genome, whole exome, and targeted panel sequencing from 1141 newly diagnosed myeloma patients. Internal samples were selected for whole exome or targeted sequencing based on previous karyotype information, or were identified in the process of other sequencing studies. The CoMMpass dataset was screened for the presence of hyperhaploidy. Hyperhaploid samples without prior karyotype information were identified by conflicting copy number profile and B allele frequency information, where the samples had incorrectly been normalized to a diploid copy number. These samples were re-normalized to a haploid copy number. Copy number, B allele frequency, and mutations of key genes were examined. Results In the entire dataset 9 hyperhaploid samples were identified, of which 2 came from the CoMMpass dataset. From those with gene expression array data, 5/7 were GEP70 high risk and all belonged to the D1 hyperdiploid gene expression subgroup. Samples had a median of 13 monosomies (range 9-14), which in general were those not associated with trisomies in hyperdiploid samples. The chromosomes traditionally trisomic in hyperdiploid myeloma were disomic in hyperhaploid myeloma. We examined the B allele frequency of these disomic chromosomes and saw that they all retained heterodisomy. Retention of heterodisomy indicates that the method of generating hyperhaploidy is through deletion of the monosomic chromosomes, rather than reverting to a haploid genome followed by duplication of some chromosomes. Retention of heterodisomy was also seen on chromosome 18, which is not normally trisomic in hyperdiploid samples, indicating that heterodisomy of chromosome 18 may be essential for a viable plasma cell clone. We examined the hyperhaploid samples for frequently mutated genes and found that 8/9 (88.8%) of hyperhaploid samples had a mutation in TP53. This rate of mutation far exceeds the overall rate of mutation in newly diagnosed patients (5.5%), indicating an oncogenic dependency in this group. The sample without mutation of TP53 had only 9 monosomies, fewer than the other samples (12-14 monosomies), indicating there may be a prognostic difference that is dependent on the total chromosome count. All samples with TP53 mutation also had monosomy of chromosome 17, indicating bi-allelic inactivation of TP53. The variant allele frequency of the TP53 mutations was high (median=0.94), indicating that bi-allelic inactivation was a clonal event. No other significant mutations were found, including those that encode chromosome segregation or kinetochore proteins. Conclusions We have previously described bi-allelic inactivation of TP53 as Double Hit myeloma, and here we identify that hyperhaploid myeloma belongs to this poor prognosis group. The method of generating the hyperhaploid clone is through deletion of chromosomes, which may happen in a way that is similar to gain of chromosomes in hyperdiploid myeloma. These Double Hit patients may be good candidates for new therapies, but using next generation sequencing techniques researchers must be careful when normalizing data to correctly identify them as hyperhaploid rather than hyperdiploid, using copy number and B allele frequency data. Disclosures Davies: MMRF: Honoraria; TRM Oncology: Honoraria; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy; ASH: Honoraria. Morgan:Takeda: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Janssen: Research Funding; Celgene: Consultancy, Honoraria, Research Funding." @default.
• W2913132598 created "2019-02-21" @default.
• W2913132598 creator A5003642180 @default.
• W2913132598 creator A5006381166 @default.
• W2913132598 creator A5011515629 @default.
• W2913132598 creator A5015802614 @default.
• W2913132598 creator A5016246851 @default.
• W2913132598 creator A5034560778 @default.
• W2913132598 creator A5042546543 @default.
• W2913132598 creator A5065773774 @default.
• W2913132598 creator A5071448111 @default.
• W2913132598 creator A5087775484 @default.
• W2913132598 creator A5090044223 @default.
• W2913132598 date "2018-11-29" @default.
• W2913132598 modified "2023-10-17" @default.
• W2913132598 title "Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53" @default.
• W2913132598 doi "https://doi.org/10.1182/blood-2018-99-113102" @default.
• W2913132598 hasPublicationYear "2018" @default.
• W2913132598 type Work @default.
• W2913132598 sameAs 2913132598 @default.
• W2913132598 citedByCount "0" @default.
• W2913132598 crossrefType "journal-article" @default.
• W2913132598 hasAuthorship W2913132598A5003642180 @default.
• W2913132598 hasAuthorship W2913132598A5006381166 @default.
• W2913132598 hasAuthorship W2913132598A5011515629 @default.
• W2913132598 hasAuthorship W2913132598A5015802614 @default.
• W2913132598 hasAuthorship W2913132598A5016246851 @default.
• W2913132598 hasAuthorship W2913132598A5034560778 @default.
• W2913132598 hasAuthorship W2913132598A5042546543 @default.
• W2913132598 hasAuthorship W2913132598A5065773774 @default.
• W2913132598 hasAuthorship W2913132598A5071448111 @default.
• W2913132598 hasAuthorship W2913132598A5087775484 @default.
• W2913132598 hasAuthorship W2913132598A5090044223 @default.
• W2913132598 hasBestOaLocation W29131325981 @default.
• W2913132598 hasConcept C104317684 @default.
• W2913132598 hasConcept C10590036 @default.
• W2913132598 hasConcept C120821319 @default.
• W2913132598 hasConcept C141231307 @default.
• W2913132598 hasConcept C143191323 @default.
• W2913132598 hasConcept C16671776 @default.
• W2913132598 hasConcept C180754005 @default.
• W2913132598 hasConcept C203014093 @default.
• W2913132598 hasConcept C2776364478 @default.
• W2913132598 hasConcept C2779142324 @default.
• W2913132598 hasConcept C30481170 @default.
• W2913132598 hasConcept C501734568 @default.
• W2913132598 hasConcept C53226629 @default.
• W2913132598 hasConcept C54355233 @default.
• W2913132598 hasConcept C86803240 @default.
• W2913132598 hasConceptScore W2913132598C104317684 @default.
• W2913132598 hasConceptScore W2913132598C10590036 @default.
• W2913132598 hasConceptScore W2913132598C120821319 @default.
• W2913132598 hasConceptScore W2913132598C141231307 @default.
• W2913132598 hasConceptScore W2913132598C143191323 @default.
• W2913132598 hasConceptScore W2913132598C16671776 @default.
• W2913132598 hasConceptScore W2913132598C180754005 @default.
• W2913132598 hasConceptScore W2913132598C203014093 @default.
• W2913132598 hasConceptScore W2913132598C2776364478 @default.
• W2913132598 hasConceptScore W2913132598C2779142324 @default.
• W2913132598 hasConceptScore W2913132598C30481170 @default.
• W2913132598 hasConceptScore W2913132598C501734568 @default.
• W2913132598 hasConceptScore W2913132598C53226629 @default.
• W2913132598 hasConceptScore W2913132598C54355233 @default.
• W2913132598 hasConceptScore W2913132598C86803240 @default.
• W2913132598 hasIssue "Supplement 1" @default.
• W2913132598 hasLocation W29131325981 @default.
• W2913132598 hasLocation W29131325982 @default.
• W2913132598 hasOpenAccess W2913132598 @default.
• W2913132598 hasPrimaryLocation W29131325981 @default.
• W2913132598 hasRelatedWork W1852779397 @default.
• W2913132598 hasRelatedWork W1970446973 @default.
• W2913132598 hasRelatedWork W1998030944 @default.
• W2913132598 hasRelatedWork W2014964654 @default.
• W2913132598 hasRelatedWork W2024378792 @default.
• W2913132598 hasRelatedWork W2040267378 @default.
• W2913132598 hasRelatedWork W2318511135 @default.
• W2913132598 hasRelatedWork W2610593425 @default.
• W2913132598 hasRelatedWork W2768522891 @default.
• W2913132598 hasRelatedWork W2789615884 @default.
• W2913132598 hasVolume "132" @default.
• W2913132598 isParatext "false" @default.
• W2913132598 isRetracted "false" @default.
• W2913132598 magId "2913132598" @default.
• W2913132598 workType "article" @default.